A Biomarker to Differentiate between Primary and Cocaine-Induced Major Depression in Cocaine Use Disorder: The Role of Platelet IRAS/Nischarin (I 1 -Imidazoline Receptor).

Autor:	Keller B; Laboratori de Neurofarmacologia, IUNICS, Universitat de les Illes Balears (UIB), Fundació Institut d'Investigació Sanitària Illes Balears (IdISBa), Palma, Majorca, Spain.; Redes Temáticas de Investigación Cooperativa en Salud - Red de Trastornos Adictivos (RETICS-RTA), Instituto de Salud Carlos III (ISCIII), Madrid, Spain., Mestre-Pinto JI; Redes Temáticas de Investigación Cooperativa en Salud - Red de Trastornos Adictivos (RETICS-RTA), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.; Hospital del Mar Medical Research Institute (IMIM), Institut de Neuropsiquiatria i addiccions (INAD), Barcelona, Spain., Álvaro-Bartolomé M; Laboratori de Neurofarmacologia, IUNICS, Universitat de les Illes Balears (UIB), Fundació Institut d'Investigació Sanitària Illes Balears (IdISBa), Palma, Majorca, Spain.; Redes Temáticas de Investigación Cooperativa en Salud - Red de Trastornos Adictivos (RETICS-RTA), Instituto de Salud Carlos III (ISCIII), Madrid, Spain., Martinez-Sanvisens D; Redes Temáticas de Investigación Cooperativa en Salud - Red de Trastornos Adictivos (RETICS-RTA), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.; Hospital del Mar Medical Research Institute (IMIM), Institut de Neuropsiquiatria i addiccions (INAD), Barcelona, Spain., Farre M; Redes Temáticas de Investigación Cooperativa en Salud - Red de Trastornos Adictivos (RETICS-RTA), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.; Hospital del Mar Medical Research Institute (IMIM), Institut de Neuropsiquiatria i addiccions (INAD), Barcelona, Spain.; Hospital Universitari Germans Trias i Pujol (IGTP), Badalona, Spain.; Universitat Autònoma de Barcelona (UAB), Barcelona, Spain., García-Fuster MJ; Laboratori de Neurofarmacologia, IUNICS, Universitat de les Illes Balears (UIB), Fundació Institut d'Investigació Sanitària Illes Balears (IdISBa), Palma, Majorca, Spain.; Redes Temáticas de Investigación Cooperativa en Salud - Red de Trastornos Adictivos (RETICS-RTA), Instituto de Salud Carlos III (ISCIII), Madrid, Spain., García-Sevilla JA; Laboratori de Neurofarmacologia, IUNICS, Universitat de les Illes Balears (UIB), Fundació Institut d'Investigació Sanitària Illes Balears (IdISBa), Palma, Majorca, Spain.; Redes Temáticas de Investigación Cooperativa en Salud - Red de Trastornos Adictivos (RETICS-RTA), Instituto de Salud Carlos III (ISCIII), Madrid, Spain., Torrens M; Redes Temáticas de Investigación Cooperativa en Salud - Red de Trastornos Adictivos (RETICS-RTA), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.; Hospital del Mar Medical Research Institute (IMIM), Institut de Neuropsiquiatria i addiccions (INAD), Barcelona, Spain.; Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
Jazyk:	angličtina
Zdroj:	Frontiers in psychiatry [Front Psychiatry] 2017 Dec 01; Vol. 8, pp. 258. Date of Electronic Publication: 2017 Dec 01 (Print Publication: 2017).
DOI:	10.3389/fpsyt.2017.00258
Abstrakt:	The association of cocaine use disorder (CUD) and comorbid major depressive disorder (MDD; CUD/MDD) is characterized by high prevalence and poor treatment outcomes. CUD/MDD may be primary (primary MDD) or cocaine-induced (CUD-induced MDD). Specific biomarkers are needed to improve diagnoses and therapeutic approaches in this dual pathology. Platelet biomarkers [5-HT 2A receptor and imidazoline receptor antisera selected (IRAS)/nischarin] were assessed by Western blot in subjects with CUD and primary MDD ( n  = 16) or CUD-induced MDD ( n  = 9; antidepressant free, AD-; antidepressant treated, AD+) and controls ( n  = 10) at basal level and/or after acute tryptophan depletion (ATD). Basal platelet 5-HT 2A receptor (monomer) was reduced in comorbid CUD/MDD subjects (all patients: 43%) compared to healthy controls, and this down-regulation was independent of AD medication (decreases in AD-: 47%, and in AD+: 40%). No basal differences were found for IRAS/nischarin contents in AD+ and AD- comorbid CUD/MDD subjects. The comparison of IRAS/nischarin in the different subject groups during/after ATD showed opposite modulations (i.e., increases and decreases) in response to low plasma tryptophan levels with significant differences discriminating between the subgroups of CUD with primary MDD and CUD-induced MDD. These specific alterations suggested that platelet IRAS/nischarin might be useful as a biomarker to discriminate between primary and CUD-induced MDD in this dual pathology.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu